Article
CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.
Molecular genetics and genomics : MGG - 1 Jan 2023
Khiabani Alireza, Kohansal Mohammad Hasan, Keshavarzi Aref, Shahraki Hojat, Kooshesh Mohsen, Karimzade Mohammadreza, Gholizadeh Navashenaq Jamshid
Abstract excerpt
The CRISPR/Cas9 technique is easily programmable, fast, more powerful, and efficient at generating a mutation compared to previous gene therapy methods. β-thalassemia is the most common autosomal recessive disorder worldwide. Appropriate genomic changes in the β gene can be modified to alleviate the symptoms of the disease using the CRISPR/Cas9 system. PubMed/Medline, Scopus, Web of Science, and SID databases...
Topics
- Humans
- CRISPR-Cas Systems
- Gene Editing
- beta-Thalassemia
- Mutation